- COVID-19 disease has shown propensity to affect patients’ long-term health by affecting cardiovascular and pulmonary systems
- Medical practitioners have increasingly turned towards ultrasound machines to scan critical organs while simultaneously limiting their exposure to potentially contagious patients
- Mediscan’s cloud-based ultrasound software allows medical professionals to accurately view and diagnose internal issues through 3D musculoskeletal, lung, cardiac imaging
COVID-19 has shown a propensity to affect an individual’s body in a number of different ways, including the long-term health of a patient’s cardiovascular and pulmonary system. As such, the need to properly diagnose lung infections, which could otherwise be sustained throughout a patient’s life, or myocarditis, an inflammation of the heart muscles which could go undiscovered if not properly diagnosed, has heightened the need for medical practitioners to make use of the proper technology to enable early diagnosis. Healthtech Solutions (OTC: HLTT), through its Mediscan Inc. subsidiary, has developed a cloud-based software for ultrasound technology which has proven to be highly effective in diagnosing internal organs potentially affected by COVID-19. Moreover, ultrasounds have also shown an ability to monitor a patient’s vital signs and single out any potential abnormalities.
Ultrasound, a fast-evolving technology, can provide an immediate diagnosis of an internal issue in a patient’s body. When a symptomatic patient is suffering from COVID-19, bedside ultrasound is commonly used to scan critical organs, such as the heart, for damage (https://ibn.fm/BNrjM). Thus, ultrasounds can both avoid the need for patients to undergo potentially invasive physical examinations while simultaneously limiting the exposure to which medical practitioners may be subjected when dealing with the individual.
Mediscan’s technology has shown great success in musculoskeletal (“MSK”), lung and cardiac imaging, enabling rapid pathology evaluation. Scanning the lung or the MSK sub-system, Mediscan directly images the target area being checked, saves it as a reference, and then automatically compares it to previous images. This enables it to determine the changes in a patient’s condition.
In addition to its utility in MSK, lung and cardiac imaging, the use of portable ultrasounds equipped with Mediscan’s cloud-based software application provides healthcare providers with a flexible and easy-to-use solution through which to accurately evaluate, triage and diagnose COVID-19’s effects on contagious patients in isolation. This is particularly useful in situations where traditional MRI’s, CET or PET scans are otherwise not accessible.
Traditional ultrasound technology has long relied on producing 2D-grayscale images, which Mediscan’s technology can transform into a digital 3D-HD format. Once an image has been captured in 2D, Mediscan’s software can convert it using its proprietary cloud-based software application process, providing medical professionals with 3D medical images of different organs, including the heart, lungs, tendons, skin and nerves.
COVID-19 can vary in the way it affects the body, ranging from mild and negligible symptoms to much more life-threatening forms. However, in all cases, it is necessary to diagnose each patient and search for potential pulmonary or cardiac damage as a priority. An early diagnosis can play a critical role in ensuring a patient’s full recovery, with technologies like ultrasounds playing an increasingly important role.
The widening scope of clinical applications for Mediscan’s ultrasound-based technology as well as its growing potential to serve as an early diagnosis tool for coronavirus-linked organ damage has further boosted the company’s growth prospects within the North American medical imaging market, an industry which boasted an addressable target market size of $134 billion as of 2020 (https://ibn.fm/TSPAW).
For more information, visit the company’s website at www.MyMediScan.com.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.